CYCLO THERAPEUTICS INC (CYTH)       2.125  +0.16 (+7.92%)

2.125  +0.16 (+7.92%)

US23254X2018 - Common Stock - After market: 2.2 +0.08 (+3.53%)

CYCLO THERAPEUTICS INC2.125

NASDAQ:CYTH (10/4/2022, 7:20:14 PM)+0.16 (+7.92%)

After market: 2.2 +0.08 (+3.53%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-16 2022-08-16/bmo Earnings (Next) 11-14 2022-11-14
Ins Owners 6.01% Inst Owners 4.77%
Market Cap 17.93M Shares 8.44M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 82.86
IPO 02-27 2004-02-27

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CYTH Daily chart

Company Profile

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 9 full-time employees. The company went IPO on 2004-02-27. The firm's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The company is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The firm's product lines include Trappsol and Aquaplex. The company sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The firm also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

Company Info

CYCLO THERAPEUTICS INC

6714 Nw 16Th Street,, Suite B

Gainesville Florida FLORIDA 32653

P: 13864188060.0

CEO: N. Scott Fine

Employees: 9

Website: https://www.cyclotherapeutics.com/

CYTH Twits

Here you can normally see the latest stock twits on CYTH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example